15
Participants
Start Date
June 30, 2025
Primary Completion Date
June 30, 2030
Study Completion Date
June 30, 2030
Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
A minimum of 6 and a maximum of 15 patients will be enrolled to receive first-line chemotherapy (gem/nab-P or mFOLFIRINOX) in combination with sotorasib 960 mg daily (QD). The treatment with gem/nab-P and mFOLFIRINOX should be managed as per clinical practice.
Sainte Catherine - Institut Avignon Provence, Avignon
Chu Besançon - Hôpital Jean Minjoz, Besançon
Chu Brest - Hôpital Morvan, Brest
Chu de Lille - Claude Huriez, Lille
Hôpital Léon Berard, Lyon
Chu Bordeaux - Hôpital Haut Lévêque, Pessac
Chu Poitiers, Poitiers
Chu Reims - Hôpital Robert Debré, Reims
Chu Toulouse, Toulouse
Hôpital Paul-Brousse, Villejuif
Hospital Universitario Miguel Servet, Zaragoza
Hospital Universitari Vall D'Hebron, Barcelona
Institut Català D'Oncologia L'Hospitalet (Ico), Barcelona
Hospital Universitario Marqués de Valdecilla, Santander
Hospital Reina Sofía, Córdoba
Hospital Universitario Donostia-Donostia Unibertsitate Ospitalea, Donostia / San Sebastian
Hospital Clínico San Carlos, Madrid
Hospital General Universitario Gregorio Marañón, Madrid
Hospital Universitario 12 de Octubre, Madrid
Complejo Hospitalario Regional de Málaga, Málaga
Complejo Hospitalario de Navarra, Pamplona
Complexo Hospitalario Universitario de Ourense, Ourense
Hospital Universitario Central de Asturias, Oviedo
Hospital Universitario de Salamanca, Salamanca
Hospital General Universitario de Valencia, Valencia
Apices Soluciones S.L.
INDUSTRY
GERCOR - Multidisciplinary Oncology Cooperative Group
OTHER
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
OTHER